Esprit BTK Post-Approval Study
NCT: NCT06656364 · ACTIVE_NOT_RECRUITING
Brief Summary
The Esprit BTK PAS is a prospective, single-arm, multi-center observational study to assess the continued safety and effectiveness of the Esprit™ BTK Everolimus Eluting Resorbable Scaffold System under commercial use, in patients with diseased infrapopliteal lesions causing CLTI (Chronic Limb-Threatening Ischemia) in a real-world setting. The clinical investigation will be conducted at up to 50 sites in the United States (US) and additional sites may be added outside of the US (OUS). Approximately 200 patients with a minimum of 50% of patients in the US will be registered in the clinical investigation.
Frequently Asked Questions
What is Esprit BTK Post-Approval Study?
Esprit BTK Post-Approval Study is a clinical trial registered under NCT06656364. Current status: ACTIVE_NOT_RECRUITING.
What is the status of NCT06656364?
The current status of NCT06656364 (Esprit BTK Post-Approval Study) is: ACTIVE_NOT_RECRUITING.
When did Esprit BTK Post-Approval Study start?
Esprit BTK Post-Approval Study started on 2024-10-21.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.